藥明生物跌幅擴至17% 數隻藥股挫逾5%-7% 三葉草逆升9%
藥明生物(02269.HK)午後跌幅持續擴大,股價一舉失守20天、10天及50天線(43.7-46.3元),最低見38.5元,現報38.85元,急挫17%,成交急增至7,882萬股,創逾五個月高。
其餘醫藥股普遍難以獨善其身,信達生物(01801.HK)午後失守250天線(34.9元),最多挫逾7%低見33元,現報33.35元,續跌6.3%。
金斯瑞生物(01548.HK)、藥明康德(02359.HK)、再鼎醫藥-B(09688.HK)、泰格醫藥(03347.HK)、維亞生物(01873.HK)及諾誠健華-B(09969.HK)也挫近6%-7.5%,報17.84元、67.1元、21.9元、48.7元、1.65元及7.43元,股價均失守10天線。
藍籌翰森製藥(03692.HK)、科濟藥業-B(02171.HK)、康方生物-B(09926.HK)、威高股份(01066.HK)、康希諾(06185.HK)及君實生物(01877.HK)跌近3%-5%。
然而,三葉草生物1-B(02197.HK)逆升9%報1.22元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.